Valsartan may be used alone for the management of hypertension [FDA label]
Valsartan is indicated for the management of hypertension in patients for whom combination therapy is deemed appropriate [F3139]. It is combined with other anthypertensive agents such as hydrochlorothiazide, amlodipine, nevibolol and sacubitril [F3139], [F3136], [F3145], [F3148].
Valsartan is indicated for the treatment of heart failure (NYHA class II-IV) in patients who are intolerant to angiotensin-converting enzyme inhibitors (ACE inhibitors) for various reasons, including those who experience ACE inhibitor adverse effects. In a clinical study of 5010 patients, hospitalizations due to heart failure were markedly decreased when valsartan was taken regularly over a 2-year span [FDA label].
|DB00275||Olmesartan||Olmesartan is indicated for the treatment of hypertension either alone or associated with other antihypertensive agents.[FDA label]
Hypertension is a sustained elevation of resting blood pressure. The hypertensive effect can affect the systolic blood pressure, diastolic blood pressure or both. This condition tends to be asymptomatic until it reaches a severe or long-standing state.[L5569]|
|DB00678||Losartan||Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension.[L7423] Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).[L7426]|
|DB00796||Candesartan cilexetil||May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.|
|DB00876||Eprosartan||For the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors).|
|DB00966||Telmisartan||Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).|
|DB01029||Irbesartan||Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria.[L7456] A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.[L7459]|
|DB01347||Saprisartan||Saprisartan is used in the treatment of hypertension and heart failure.|
|DB01349||Tasosartan||Tasosartan is infrequently in the treatment of hypertension and heart failure.|
|DB08822||Azilsartan medoxomil||Treatment of hypertension (alone or as an adjunct).|
|DB01342||Forasartan||For the treatment of hypertension.|
|DB09279||Fimasartan||Used for the treatment of hypertension and heart failure [A20319].|